A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Jul 2017
At a glance
- Drugs ACT 709478 (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Actelion Pharmaceuticals
- 26 Jul 2017 Status changed from not yet recruiting to recruiting.
- 06 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 24 Jul 2017.
- 29 May 2017 New trial record